Skip to main content
SpringerLink
Log in

The New NCI Screen and Its Implications for Clinical Evaluation

  • Chapter
New Anticancer Drugs

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 70))

Abstract

The primary objective of an antitumor screening program is to select from the universe of synthetic and natural products, for development and introduction into the clinic, those with the greatest likelihood of usefulness in the treatment of clinical cancer. The experimental tumor screening systems that have been employed in the search for new antitumor agents have resulted in the discovery of drugs of considerable value in the treatment of human neoplasia, and for certain types of cancer chemotherapy have contributed to an increase in lifespan that approaches normal life expectancy [13, 27]. Included are Burkitt’s lymphoma, choriocarcinoma, acute lymphocytic leukemia, Hodgkin’s disease, lymphosarcoma, mycosis fungoides, embryonal testicular carcinoma, Wilms’ tumor, Ewing’s sarcoma, rhabdosarcoma, and retinoblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cain, B. F., Atwell, G. J.: The experimental antitumor properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur. J. Cancer 10, 539 (1974)

    PubMed  CAS  Google Scholar 

  2. Carter, S. K.: Some thoughts on experimental screening. Biomedicine 22, 5 (1975)

    PubMed  CAS  Google Scholar 

  3. Carter, S. K., Goldin, A.: Experimental models and their clinical correlations. In: USA-USSR Monograph, Methods of development of new anticancer drugs, p. 63; DHEW publication No. [NIH] 76–1037 (1977)

    Google Scholar 

  4. Collins, K. D., Stark, G. R.: Aspartate transcarbamylase. Interaction with the transition state analog, N-(phosphonacetyl)-L-aspartate. J. Biol. Chem. 246, 6599 (1971)

    PubMed  CAS  Google Scholar 

  5. Connors, T. A., Cumber, A. J., Ross, W. C. J., Clarke, S. A., Mitchley, B. C. V.: Regression of human lung xenografts induced by water-soluble analogs of hexamethylmelamine. Cancer Treat. Rep. 61, 927 (1977)

    PubMed  CAS  Google Scholar 

  6. Corbett, T. H., Griswold, D. P., Jr., Roberts, B.J., Peckham, J. C., Schabel, F. M., Jr.: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40, 2660 (1977)

    Article  PubMed  CAS  Google Scholar 

  7. Detre, S. I., Davies, A. J. S., Connors, T. A.: New models for cancer chemotherapy. Cancer Chemother. Rep. [Part 2] 5, 133 (1975)

    Google Scholar 

  8. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. M., Abbott, B. J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd ed.). Cancer Chemother. Rep. [Part 3] 3, 1 (1972)

    Google Scholar 

  9. Giovanella, B. C., Stehlin, J. S., Williams, L. J., Jr.: Heterotransplantation of human malignant tumors in ‘nude’ thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl. Cancer Inst. 52, 921 (1974)

    PubMed  CAS  Google Scholar 

  10. Goldin, A., Serpick, A. A., Mantel, N.: A commentary — Experimental screening procedures and clinical predictability value. Cancer Chemother. Rep. 50, 173 (1966)

    PubMed  CAS  Google Scholar 

  11. Goldin, A., Schepaitz, S. A., Venditti, J. M., DeVita, V. T., Jr.: Historical development and current strategy of the National Cancer Institute drug development program. In: Methods in cancer research. Vol. 16 [pp. 165–245] DeVita, V. T. Jr., Busch, H. (eds.) New York: Academic 1979

    Google Scholar 

  12. Hanka, L. J., Martin, D. G., Neil, G. L.: A new antitumor antimetabolite, (αS, 5 S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC 163501): Microbial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo. Cancer Chemother. Rep. 57, 141 (1973)

    PubMed  CAS  Google Scholar 

  13. Johnson, R. K., Goldin, A.: The clinical impact of screening and other experimental tumor studies. Cancer Treat. Rev. 2, 1 (1975)

    Article  PubMed  CAS  Google Scholar 

  14. Johnson, R. K., Inouye, T., Goldin, A., Stark, G. R.: Antitumor activity of N-(phosphonacetyl)-L-aspartic acid; a transition-state inhibitor of aspartate transcarbamylase. Cancer Res. 36, 2720 (1976)

    PubMed  CAS  Google Scholar 

  15. Johnson, R. K., Swyryd, E. A., Stark, G. R.: Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase. Cancer Res. 38, 371 (1978)

    PubMed  CAS  Google Scholar 

  16. Kuga, N., Yoshida, K., Seido, T., Oboshi, S., Koide, T., Shimosato, Y., Nomura, T.: Heterotransplantations of cultured human cancer cells and human cancer tissues into nude mice. Gann 66, 547 (1975)

    PubMed  CAS  Google Scholar 

  17. Livingston, R. B., Venditti, J. M., Cooney, D. A., Carter, S. K.: Glutamine antagonists in cancer chemotherapy. In: Advances in pharmacology and chemotherapy. Vol. 8, p. 57. Garattini, S., Goldin, A., Hawking, F., Kopin, I. J. (eds.) New York: Academic 1970

    Google Scholar 

  18. Martin, D. S., Fugmann, R. A., Stolfi, R. L., Hayworth, P. E.: Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother. Rep. [Part 2] 5, 89 (1975)

    Google Scholar 

  19. Mitchley, B. C. V., Clarke, S. A., Connors, T. A.: Hexamethylmelamine-induced regression of human lung tumors growing in immune deprived mice. Cancer Res. 35, 1099 (1975)

    PubMed  CAS  Google Scholar 

  20. Osieka, R., Houchens, D. P., Goldin, A., Johnson, R. K.: Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40, 2640 (1977)

    Article  PubMed  CAS  Google Scholar 

  21. Rothenberg, L., Terselic, R. A.: Commentary: Management of the National Cancer Institute’s drug research program through application of the linear array concept. Cancer Chemother. Rep. 54, 303 (1970)

    PubMed  CAS  Google Scholar 

  22. Schabel, F. M., Jr., Laster, W. R., Jr., Rose, W. C.: Experimental tumors and tumor cell kinetics: The Role of experimental tumor systems. In: Progress in Cancer Research and therapy. Vol. II. Lung Cancer: Progress in Therapeutic Research. Muggia, F.M., Rozencweig, M. (eds.) New York: Raven 15–35, 1979

    Google Scholar 

  23. Schepartz, S. A.: Antitumor-screening procedures of the National Cancer Institute. Jpn. J. Antibiot. 30, [Suppl.], 35 (1977)

    PubMed  Google Scholar 

  24. Shimosato, Y., Kameya, T., Nagai, K., Hirohashi, S., Koide, T., Hayashi, H., Nomura, T.: Transplantation of human tumors in nude mice. J. Natl. Cancer Inst. 56, 1251 (1976)

    PubMed  CAS  Google Scholar 

  25. Venditti, J. M.: Relevance of transplantable animal-tumor systems to the selection of new agents for clinical trial. In: Pharmacological basis of cancer chemotherapy. p. 245. Baltimore: Williams and Wilkins 1975

    Google Scholar 

  26. Venditti, J. M., Goldin, A., Miller, I., Rozencweig, M.: Experimental models for antitumor testing in current use by the National Cancer Institute, USA. Statistical analysis and methods for selecting agents for clinical trials. Advances in Cancer Chemotherapy, H. Umezawa et al. (eds.). Japan, Sci. Soc. Press, Tokyo-Univ. Park Press, Baltimore, pp. 201–219, 1978

    Google Scholar 

  27. Zubrod, C. G.: Chemical control of cancer. Proc. Natl. Acad. Sci. USA 69, 1042 (1972)

    Article  CAS  Google Scholar 

  28. Zubrod, C. G., Schepartz, S., Leiter, J., Endicott, K. M., Carrese, L. M., Baker, C. G.: The chemotherapy program of the National Cancer Institute: History, analysis and plans. Cancer Chemother. Rep. 50, 349 (1966)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, MD, 20014, USA

    Abraham Goldin & John M. Venditti

Authors
  1. Abraham Goldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Rd., Bldg. 3, Suite 200, 94304, Palo Alto, Cal., USA

    Stephen K. Carter

  2. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Ikebukuro-kami 1-37-1, Toshima-ku, Tokyo 170, Japan

    Yoshia Sakurai

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldin, A., Venditti, J.M. (1980). The New NCI Screen and Its Implications for Clinical Evaluation. In: Carter, S.K., Sakurai, Y. (eds) New Anticancer Drugs. Recent Results in Cancer Research, vol 70. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81392-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81392-4_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81394-8

  • Online ISBN: 978-3-642-81392-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation